Tourmaline Bio, Inc.
NASDAQ: TRML0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sandeep C. Kulkarni
- Employees
- 74
- Headquarters
- New York City, United States
- IPO year
- 2021
- Market cap
- $1.2B
- Website
- https://www.tourmalinebio.com
Loading TRML…
Loading profile data…Frequently asked questions about TRML
What does Tourmaline Bio, Inc. (TRML) do?
Tourmaline Bio, Inc. is a clinical-stage biotechnology firm committed to advancing therapies for individuals suffering from debilitating immune disorders. The company's development pipeline focuses on conditions such as Atherosclerotic Cardiovascular Disease (ASCVD) and Thyroid Eye Disease (TED). Established in 2021, this enterprise is headquart...
Where does TRML trade?
Tourmaline Bio, Inc. (TRML) trades on the NASDAQ Global Select.
What sector is TRML in?
Tourmaline Bio, Inc. (TRML) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Tourmaline Bio, Inc.?
Sandeep C. Kulkarni is the chief executive officer of Tourmaline Bio, Inc. (TRML).
Where is Tourmaline Bio, Inc. headquartered?
Tourmaline Bio, Inc. is headquartered in United States.
Does TRML pay a dividend?
Tourmaline Bio, Inc. (TRML) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TRML go public?
Tourmaline Bio, Inc. (TRML) completed its initial public offering in 2021.